pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Azstarys
drug
save

(dexmethylphenidate hydrochloride + serdexmethylphenidate chloride ER)

Marketedupdated 3mo ago
by Corium LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 6
  • tagApproval8 co-mentions · 4 sources
  • tagSmall Molecule4 co-mentions · 4 sources
  • drugDEXMETHYLPHENIDATE HYDROCHLORIDE4 co-mentions · 4 sources
  • drugdexmethylphenidate hydrochloride ER4 co-mentions · 4 sources
  • drugdexmethylphenidate hydrochloride XR4 co-mentions · 4 sources
  • drugFOCALIN XR4 co-mentions · 4 sources

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 27, 2032
~6.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Dec 9, 2037compositionUS 10584112
  • Dec 9, 2037compositionUS 10584112
  • Dec 9, 2037compositionUS 10584112
  • Dec 9, 2037formulationUS 10584113
  • Dec 9, 2037formulationUS 10584113
  • Dec 9, 2037formulationUS 10584113
  • Dec 9, 2037formulationUS 10759778
  • Dec 9, 2037formulationUS 10759778
  • Dec 9, 2037formulationUS 10759778
  • Dec 9, 2037method-of-use (U-3094)US 10858341
  • Dec 9, 2037method-of-use (U-3094)US 10858341
  • Dec 9, 2037method-of-use (U-3094)US 10858341
  • Dec 9, 2037method-of-use (U-3094)US 10954213
  • Dec 9, 2037method-of-use (U-3094)US 10954213
  • Dec 9, 2037method-of-use (U-3094)US 10954213
  • Jul 27, 2032formulationUS 9079928
  • Jul 27, 2032formulationUS 9079928
  • Jul 27, 2032formulationUS 9079928

FDA exclusivities (3)

  • May 7, 2026NCENew Chemical Entity (5y)
  • May 7, 2026NCENew Chemical Entity (5y)
  • May 7, 2026NCENew Chemical Entity (5y)

News(0)

no news has mentioned this drug yet

brand
Azstarys
generic
(dexmethylphenidate hydrochloride + serdexmethylphenidate chloride)
indication
Attention Deficit Hyperactivity Disorder (ADHD)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 54m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?